PriceTargets.com logo

TNF Pharmaceuticals - TNFA Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.67 As of 12/3/2025 01:00 AM ET
▲ +1.29 (38.17%)

This chart shows the closing price for TNFA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TNF Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNFA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNFA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for TNF Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.67.

This chart shows the closing price for TNFA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 polled investment analysts is to sell stock in TNF Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/27/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
TNF Pharmaceuticals logo
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Read More

Today's Range

Now: $4.67
Low: $3.82
High: $5.68

50 Day Range

MA: $3.87
Low: $2.76
High: $5.75

52 Week Range

Now: $4.67
Low: $3.24
High: $195.00

Volume

54,712,457 shs

Average Volume

3,511,287 shs

Market Capitalization

$8.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04

Frequently Asked Questions

What sell-side analysts currently cover shares of TNF Pharmaceuticals?

The following Wall Street analysts have issued reports on TNF Pharmaceuticals in the last year: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for TNFA.

What is the current price target for TNF Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for TNF Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for TNF Pharmaceuticals in the next year.
View the latest price targets for TNFA.

What is the current consensus analyst rating for TNF Pharmaceuticals?

TNF Pharmaceuticals currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe TNFA will underperform the market and that investors should sell shares of TNF Pharmaceuticals.
View the latest ratings for TNFA.

What other companies compete with TNF Pharmaceuticals?

Other companies that are similar to TNF Pharmaceuticals include Dare Bioscience, iBio, Mana Capital Acquisition, Neuphoria Therapeutics and Lixte Biotechnology. Learn More about companies similar to TNF Pharmaceuticals.

How do I contact TNF Pharmaceuticals' investor relations team?

TNF Pharmaceuticals' physical mailing address is 855 N. Wolfe Street, Suite 623, Baltimore, MD 21205, United States. The company's listed phone number is (856) 848-8698 and its investor relations email address is [email protected]. The official website for TNF Pharmaceuticals is tnfpharma.com. Learn More about contacing TNF Pharmaceuticals investor relations.